A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Inclusion Criteria:

• Moderate to severe OA pain (corresponding to NRS Pain ≥5 to ≤9) in the target kneefor the majority of days in the last 3 months prior to Screening

• KOOS pain subscale <60 for the target knee during Screening

• High sensitivity C-reactive Protein (hsCRP) ≥1.8 mg/L

• Radiographic KL grade 2 to 4 knee OA and joint space width (JSW) 2.0-4.0 mm (men) or 1.5-3.5 mm (women) in the medial tibiofemoral compartment (TFC) in the target knee

• Contrast-enhanced MRI (CE-MRI) diagnosed moderate or severe knee synovitis based onan established synovititis scoring system (moderate score 9-12 or severe score ≥13)

Exclusion Criteria:

• History of, or planned; knee replacement (partial or total) in either knee;arthroscopy or lavage in either knee within 6 months prior to screening; any otherprevious surgical intervention in the target knee, or for the contralateral kneewithin 12 months prior to Screening, including mosaicplasty, microfracture,meniscectomy >50% or osteotomy

• Moderate to severe pain in the contralateral knee for the majority of days in thelast 3 months prior to screening

• Malalignment >7.5° in the target knee (either varus or valgus)

• Any diagnosis of systemic inflammatory arthritis or connective tissue disease,including but not limited to rheumatoid arthritis, psoriatic arthritis, ankylosingspondylitis, gout, Paget's disease, systemic lupus erythematosus) or other systemiccondition that might confound assessment of OA (e.g. fibromyalgia)

• Ipsilateral hip OA or hip prosthesis recently implanted (within 1 year prior toscreening) or hip replacement on either side planned within the study period